Fig. 1From: Momelotinib: an emerging treatment for myelofibrosis patients with anemiaSystemic iron homeostasis and its regulation by the hepcidin-ferroportin axis. Momelotinib suppresses hepcidin expression in the liver— via inhibition of the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways— leading to an increase in circulating iron and hemoglobin levels; and restoration of erythropoiesis. Abbreviations: ACVR1 activin A receptor type 1, BMP bone morphogenetic protein, EPO erythropoietin, ERFE erythroferrone, H hepcidin, IL-6 interleukin-6, JAK Janus kinase, MMB momelotinib, RBCs red blood cells, SMAD small- mothers-against-decapentaplegic, STAT3 signal transducer and activator of transcription 3, Tf transferrinBack to article page